Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
UBS
Medtronic
Mallinckrodt
Queensland Health
Citi
Harvard Business School
Boehringer Ingelheim

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020823

« Back to Dashboard

NDA 020823 describes EXELON, which is a drug marketed by Novartis and is included in three NDAs. It is available from five suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the EXELON profile page.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the rivastigmine profile page.
Summary for 020823
Tradename:EXELON
Applicant:Novartis
Ingredient:rivastigmine tartrate
Patents:0
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020823
Mechanism of ActionCholinesterase Inhibitors
Suppliers and Packaging for NDA: 020823
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EXELON rivastigmine tartrate CAPSULE;ORAL 020823 NDA Novartis Pharmaceuticals Corporation 0078-0323 N 0078-0323-06
EXELON rivastigmine tartrate CAPSULE;ORAL 020823 NDA Novartis Pharmaceuticals Corporation 0078-0323 N 0078-0323-08

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1.5MG BASE
Approval Date:Apr 21, 2000TE:ABRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 3MG BASE
Approval Date:Apr 21, 2000TE:ABRLD:Yes

Profile for product number 005

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 4.5MG BASE
Approval Date:Apr 21, 2000TE:ABRLD:Yes

Expired US Patents for NDA 020823

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-006 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-004 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-003 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis EXELON rivastigmine tartrate CAPSULE;ORAL 020823-005 Apr 21, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Healthtrust
Johnson and Johnson
Chinese Patent Office
McKesson
Deloitte
Dow
Boehringer Ingelheim
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.